Emcure pharmaceuticals share sale: Namita Thapar, a judge in the shark tank India, may sell 2.4 percent stake through a block deal in the company, a company, a company. CNBC-TV18 has shown from sources that BC Investments IV invested by Ben Capital can sell shares for Rs 551 crore. The floor price for transactions has been kept at Rs 1,279.80 per share.
The share of the Mecre Pharma closed at Rs 1280.30 on 3 July with a 0.70 percent gains on BSE. The company’s market cap is Rs 24200 crore. The face value of the stock is Rs 10. The stock has come down 12 percent in 6 months. At the same time, 24 percent has climbed in 3 months.
The company was listed in the stock market in July 2024. Its Rs 1,952.03 crore IPO was filled 67.87 times. Namita Thapar is a hole time director in the company. So far, a record high of Rs 1,577.50 on the stock BSE and a record low of Rs 890 have been gone.
Profit increased by 64 percent in March quarter
Emcure pharmaceuticals The net consolidated profit in January-March 2025 quarter increased by 63 percent to Rs 197.23 crore on an annual basis. The profit for the owners of the holding company increased by 64 percent to Rs 188.95 crore. Consolidated revenue from the operations rose by 19.5 percent to Rs 2116 crore on an annual basis, which was Rs 1771 crore in the March 2024 quarter. Consolidated Revenue Rs 7896 crore was recorded from the operations of Makor Pharma for the entire financial year 2024-25. It was Rs 6658.25 crore a year ago. Pure consolidated profits were Rs 707.46 crore, which was Rs 527.57 crore in FY 2023-24.
The Board of McMure Pharma has recommended a final dividend of Rs 3 per share for FY 2024-25. On this, the approval of shareholders will be taken in the company’s annual general meeting. Dividend will be paid after approval. The record date for dividend is not yet decided.
Piramal Pharma Block Deal: Carlile can sell 10% stake, how many crores can be dealt with
What expects brokerage from share
The brokerage firm Kotak Institutional Equites increased the target price for the Share of Mecre Pharma after the company’s march quarterly results were released in May. Brokerage retained the “by” rating and increased the target price from ₹ 1,515 to ₹ 1,625 per. There are 3 analyst coverage on this stock right now. Two has given the rating ‘bye’, while one has given a ‘hold’ call.
Disclaimer: Advice or idea experts/brokerage firms given on Moneycontrol.com have their own personal views. The website or management is not responsible for this. Moneycontrol advises to users that always seek the advice of certified experts before taking any investment decision.